Spelling suggestions: "subject:"hemoglobin polymorphism."" "subject:"1emoglobin polymorphism.""
1 |
Chinese B thalassaemia: DNA polymorphisms andspecific mutations阮陳健貞, Tan-Un, Kian-cheng. January 1986 (has links)
published_or_final_version / Biochemistry / Doctoral / Doctor of Philosophy
|
2 |
Chinese B thalassaemia : DNA polymorphisms and specific mutations /Tan-Un, Kian-cheng. January 1986 (has links)
Thesis (Ph. D.)--University of Hong Kong, 1987.
|
3 |
Characterization of embryonic globin gene expansions in homo sapiens : mechanistic and evolutionary implicationsTitus, Elizabeth Anne Brumbaugh January 1990 (has links)
Thesis (Ph. D.)--University of Hawaii at Manoa, 1990. / Includes bibliographical references (leaves 124-138) / Microfiche. / xiii, 138 leaves, bound ill. 29 cm
|
4 |
The ovalocytosis polymorphism and malaria resistance in Papua New Guinea an epidemiological study /Cattani, Jacqueline Ann. January 1984 (has links)
Thesis (Ph. D.)--University of California, Berkeley, 1984. / Includes bibliographical references (leaves 178-188).
|
5 |
Validation of a new method for platelet HPA-1 phenotypingTaylor, James Michael January 1999 (has links)
Polymorphisms of platelet glycoproteins (GPs) are frequently targets for anti-platelet antibodies. At least 19 antigenic polymorphisms have been identified on platelet GPs. Antibodies against the HPA-lb polymorphism (a Leu to Pro switch at amino acid residue 33 of the IIIa sub-unit of GP IIb/Illa) have been attributed to as much as 90% of all cases of neonatal alloimmune thrombocytopenic purpura and posttransfusion purpura in caucasians. The HPA-lb polymorphism has also been equivocally associated with coronary artery disease, particularly early onset (<60 years of age) myocardial infarction. Current technology for identifying individuals with the HPA-lb phenotype is limited to the labor-intensive, highly technical and expensive process of DNA amplification by polymerase chain reaction and restriction fragment length polymorphism (PCR/RFLP) analysis.This study proposes an alternative method for phenotyping individuals for the HPA-1 polymorphism using the Biocytex Platelet HPA-1 kit. The kit identifies the HPA-1 polymorphism utilizing two monoclonal CD61 (platelet glycoprotein IIb/IIIa) antibodies, one of which has a lowered affinity for GP llb/Illa possessing the HPA-lb polymorphism. Fluorescent labeling of bound antibody allows for flow cytometric quantitation of antibody binding capacity (ABC) for both monoclonal antibodies, and ratios derived from the ABC can be used to phenotype previously unknown samples.The Biocytex HPA-1 kit identified 73 of 74 (98.6%) individuals possessing the HPA1 a/HPA-1 a phenotype, 22 of 22 (100%) HPA-1 a/HPA-1 b individuals and 4 of 4 (100%) HPAIb/HPA-Ib individuals. All HPA-lb phenotypes were confirmed by PCR/RFLP. Total accuracy of the test system was 99%. / Department of Biology
|
Page generated in 0.051 seconds